-$0.42 EPS Expected for Oxford Immunotec Global (OXFD) This Quarter

Analysts expect that Oxford Immunotec Global (NASDAQ:OXFD) will report earnings of ($0.42) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Oxford Immunotec Global’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.39). Oxford Immunotec Global reported earnings of ($0.36) per share in the same quarter last year, which would suggest a negative year over year growth rate of 16.7%. The firm is scheduled to announce its next earnings results before the market opens on Tuesday, May 1st.

On average, analysts expect that Oxford Immunotec Global will report full-year earnings of ($0.96) per share for the current financial year, with EPS estimates ranging from ($0.99) to ($0.94). For the next fiscal year, analysts forecast that the business will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.82) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Oxford Immunotec Global.

How to Become a New Pot Stock Millionaire

Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Tuesday, February 27th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. The company had revenue of $25.03 million for the quarter, compared to the consensus estimate of $25.12 million. Oxford Immunotec Global had a negative return on equity of 42.38% and a negative net margin of 31.90%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.22) EPS.



A number of equities analysts have recently weighed in on OXFD shares. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. Zacks Investment Research upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Tuesday, January 23rd. ValuEngine upgraded Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a report on Wednesday, March 7th. Finally, Cowen restated a “buy” rating and issued a $15.00 price objective on shares of Oxford Immunotec Global in a report on Monday, January 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Oxford Immunotec Global currently has a consensus rating of “Buy” and a consensus target price of $17.80.

Shares of OXFD traded down $0.41 during trading hours on Monday, reaching $12.53. The company’s stock had a trading volume of 53,390 shares, compared to its average volume of 145,381. The company has a market capitalization of $334.78, a price-to-earnings ratio of -9.21 and a beta of -0.32. Oxford Immunotec Global has a 1-year low of $10.00 and a 1-year high of $19.51. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.37 and a quick ratio of 4.92.

In related news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $12.01, for a total value of $36,030.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 8.11% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Oxford Immunotec Global by 5.4% during the second quarter. Vanguard Group Inc. now owns 69,043 shares of the company’s stock worth $1,161,000 after purchasing an additional 3,507 shares during the period. New York State Common Retirement Fund boosted its position in Oxford Immunotec Global by 159.6% during the third quarter. New York State Common Retirement Fund now owns 57,895 shares of the company’s stock worth $973,000 after purchasing an additional 35,595 shares during the period. Wells Fargo & Company MN boosted its position in Oxford Immunotec Global by 31.3% during the third quarter. Wells Fargo & Company MN now owns 38,720 shares of the company’s stock worth $651,000 after purchasing an additional 9,235 shares during the period. Birchview Capital LP boosted its position in Oxford Immunotec Global by 64.7% during the fourth quarter. Birchview Capital LP now owns 127,303 shares of the company’s stock worth $1,778,000 after purchasing an additional 50,000 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Oxford Immunotec Global by 9.4% during the fourth quarter. Bank of New York Mellon Corp now owns 69,740 shares of the company’s stock worth $975,000 after purchasing an additional 6,017 shares during the period. Hedge funds and other institutional investors own 93.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/04/21/0-42-eps-expected-for-oxford-immunotec-global-oxfd-this-quarter.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply